These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 31648294)
1. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Riddell SR; Maloney DG; Turtle CJ Blood; 2019 Aug; 134(7):636-640. PubMed ID: 31648294 [TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764 [TBL] [Abstract][Full Text] [Related]
3. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Gooley T; Li D; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Acharya UH; Cassaday RD; Chapuis AG; Dhawale TM; Hendrie PC; Kiem HP; Lynch RC; Ramos J; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ Blood; 2019 Apr; 133(17):1876-1887. PubMed ID: 30782611 [TBL] [Abstract][Full Text] [Related]
4. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140 [TBL] [Abstract][Full Text] [Related]
5. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL. Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599 [TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y Front Immunol; 2020; 11():564099. PubMed ID: 33329526 [TBL] [Abstract][Full Text] [Related]
8. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088 [TBL] [Abstract][Full Text] [Related]
10. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551 [TBL] [Abstract][Full Text] [Related]
12. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ghilardi G; Chong EA; Svoboda J; Wohlfarth P; Nasta SD; Williamson S; Landsburg JD; Gerson JN; Barta SK; Pajarillo R; Myers J; Chen AI; Schachter L; Yelton R; Ballard HJ; Hodges Dwinal A; Gier S; Victoriano D; Weber E; Napier E; Garfall A; Porter DL; Jäger U; Maziarz RT; Ruella M; Schuster SJ Ann Oncol; 2022 Sep; 33(9):916-928. PubMed ID: 35690221 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502 [TBL] [Abstract][Full Text] [Related]
14. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. Turtle CJ; Hanafi LA; Berger C; Gooley TA; Cherian S; Hudecek M; Sommermeyer D; Melville K; Pender B; Budiarto TM; Robinson E; Steevens NN; Chaney C; Soma L; Chen X; Yeung C; Wood B; Li D; Cao J; Heimfeld S; Jensen MC; Riddell SR; Maloney DG J Clin Invest; 2016 Jun; 126(6):2123-38. PubMed ID: 27111235 [TBL] [Abstract][Full Text] [Related]